BaFin Probe and Cancelled AGM: Gerresheimer's Twin Crises in Focus

While the DAX climbed roughly 0.9% to above 25,200 points on Tuesday, Gerresheimer shares went the other way. The pharmaceutical packaging specialist slid as much as 5.25% to EUR 26.00, bucking a broad market rally driven by semiconductor names like Infineon. The divergence underscores a deep-seated uncertainty that has yet to lift.

At the heart of the selloff is a regulatory black cloud that has been hanging over the company since March, when Germany’s financial watchdog BaFin opened an investigation into Gerresheimer’s consolidated interim financial statements. The probe targets risk assessments, potential impairments, and revenue recognition under so-called Bill-and-Hold arrangements — a practice where sales are booked before the goods physically reach the customer. Until the accounts receive a clean audit opinion, investors remain cautious.

The accounting woes came to a head on June 3, when Gerresheimer abruptly cancelled its annual general meeting because the audited annual financial statements were not ready. No replacement date has been set. The company admitted it had prematurely booked EUR 35 million in revenue and EUR 24 million in adjusted EBITDA through Bill-and-Hold transactions, a violation of IFRS standards. On top of that, non-cash impairments of between EUR 220 million and EUR 240 million are expected for fiscal 2025, hitting a U.S. facility and the Sensile Medical AG subsidiary.

Creditors have offered a temporary lifeline. Holders of Schuldschein loans worth EUR 870 million voted 96% in favour of an extension, pushing the deadline for audited accounts to September 30, 2026. Key leverage covenants have been waived in the meantime. But if that new deadline passes without certified results, the company will face acute financing pressure.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Analysts have responded with sharp downgrades. Jefferies cut its price target on May 14 from EUR 34.10 to EUR 26.80 and lowered its rating from Buy to Hold, citing delayed results and persistent market overhangs. Berenberg set a fair value of just EUR 20.00, criticising a lack of transparency and integration risks from the Bormioli Pharma acquisition. Barclays slapped an Underweight rating on the shares.

In the midst of the turmoil, one heavyweight has been quietly increasing its exposure. Goldman Sachs Asset Management now directly holds 8.75% of voting rights, with an additional 6.64% through instruments, pushing its total position to 20.04% from 19.89% previously. That makes the U.S. institution one of the largest individual shareholders.

The stock, now trading at around EUR 26.22, has lost nearly half its value over the past twelve months. From the 52-week high of EUR 50.25 set in July 2025, the decline exceeds 48%. Yet a closer look at the chart reveals a substantial recovery from the February trough of EUR 15.57 — a move that has sent the relative strength index to 82, suggesting overbought conditions on a fragile foundation.

Gerresheimer at a turning point? This analysis reveals what investors need to know now.

Looking ahead, management has outlined 2026 targets of EUR 2.3–2.4 billion in revenue, an adjusted EBITDA margin of 18–19%, and moderately positive free cash flow. All of that, however, is conditional on a favourable outcome from the BaFin investigation. If the audited accounts are published as promised in June, executives have said they will immediately announce a new date for the annual meeting. Until then, the uncertainty that sent the stock tumbling on Tuesday is likely to persist.

Ad

Gerresheimer Stock: New Analysis - 3 June

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Gerresheimer analysis...

en | DE000A0LD6E6 | BAFIN | boerse | 69474766 |